Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo4H-pyrido[1,2-a]pyrimidin-9-yl)ethylami no]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it - 026

Details for Australian Patent Application No. 2009206804 (hide)

Owner AstraZeneca AB

Inventors Gustafsson, David; Fjellstrom, Ola; Lundberg, Jan A.; Jackson, Shaun

Agent Davies Collison Cave

Pub. Number AU-A-2009206804

PCT Pub. Number WO2009/093972

Priority 61/023,498 25.01.08 US

Filing date 22 January 2009

Wipo publication date 30 July 2009

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 31/5377 (2006.01)

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

29 July 2010 PCT application entered the National Phase

  PCT publication WO2009/093972 Priority application(s): WO2009/093972

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009206818-Conveyor provided with side guard, and side guard element

2009206801-A medicament-containing dispenser provided with a display for presenting indicia to a user